The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancerSBC: 7 Hills Pharma LLC Topic: 102
Recent FDA approvals of ipilimumabnivolumaband pembrolizumabwhich target checkpoint receptors cytotoxic T lymphocyte associated antigenCTLAand programmed deathPDhave ushered in a new era of cancer immunotherapy in metastatic melanomaDespite unprecedented overall survival benefits with combination therapythe incidence of complete responses are onlyimmune related adverse eventsirAEsare increasedand ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Leukogene Therapeutics Inc. Topic: 102
Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Innovative BioChips LLC Topic: NIA
PROJECT SUMMARY Developing an Automated Yeast Dissection System for Aging ResearchAging is the single greatest risk factor for diseases that are principal causes of mortalityThe objectives of aging research are to discover key genes and pathways related to aging that may eventually contribute to retardation of aging and a delay in the onset of age associated diseasesThe budding yeast Saccharomyces ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health